Home›Trial›NCT06620627
NCT06620627RECRUITING

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

Study Summary

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

Conditions
Colorectal Cancer Screening
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NTRA
Natera Inc
Genetics Diagnostics
D48/100
Study Details
Enrollment5000 participants
Primary Completion—
Lead SponsorNatera, Inc.
Data Retrieved2026-04-11 04:23:02.260886+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 5,000 participants
Sponsor Catalyst Profile

Natera Inc (NTRA) is the sponsoring company for this trial. BiotechSign currently grades this company D (48/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTRA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.